Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Oncolytic virotherapy stories

Nov 16, 2026

CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3

CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.

Nov 16, 2026·3 sources
00
Jul 31, 2026

FDA Advisory Committee Votes 10-3 in Favor of Replimune's RP1 Efficacy Data from Ignyte Study

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.

Jul 31, 2026·1 source
00

Top claims

  • ▪Approximately 75% of newly diagnosed bladder cancers are non-muscle-invasive, a form of the disease that can recur and potentially grow into the bladder muscle
  • ▪Following the announcement of positive Phase 3 trial results on November 16, 2026, CG Oncology shares rose more than 30% to $98 in premarket trading
  • ▪Standard monitoring for intermediate-risk non-muscle-invasive bladder cancer requires patient evaluations every three months, with repeat surgical procedures performed whenever the cancer recurs

Subtopics

Cancer immunotherapy2Cancer treatment breakthroughs2Cancer & Oncology1Clinical trials1Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories